Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 10 of 15

 
 

Jazz Pharmaceuticals (NASDAQ:JAZZ)

Consensus Rating
Moderate Buy
Rating Score
2.7
Ratings Breakdown
11 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$173.07 (56.3% Upside)

About Jazz Pharmaceuticals

Jazz Pharmaceuticals logoJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$205.00 ➝ $205.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00 ➝ $140.00
8/19/2024JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$190.00 ➝ $202.00
8/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00 ➝ $140.00
8/1/2024Piper SandlerLower Price TargetOverweight ➝ Overweight$188.00 ➝ $166.00
8/1/2024Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$175.00 ➝ $174.00
8/1/2024Wells Fargo & CompanyLower Price TargetEqual Weight ➝ Equal Weight$140.00 ➝ $120.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
8/1/2024Needham & Company LLCLower Price TargetBuy ➝ Buy$208.00 ➝ $205.00
8/1/2024Robert W. BairdLower Price TargetOutperform ➝ Outperform$160.00 ➝ $154.00
 

Who are Nvidia’s New Silent Partners? (Ad)

Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.

I call these Nvidia’s “Silent Partners.”